ARCH Venture Partners — 2020 Investments
2 investments dated 2020 · listed companies and verified rows first · show all
Erasca is a clinical-stage oncology company developing therapies targeting RAS- and MAPK pathway-driven cancers using a modality-agnostic approach including small molecules, large molecules, and protein degraders.
BiotechDeep TechDigital HealthMedical DevicesSan Diego, US
Pratik S. Multani, M.D.(Director)Valerie Harding-Start(Director)Jonathan E. Lim, M.D.(President and Executive Chairman)Gary Yeung, CFA(Chief Business Officer)Alexander W. Casdin(Director)James A. Bristol, Ph.D.(Director)
PartnerKristina Burow· quoted
insitro is a drug discovery and development company that uses machine learning and cellular data to identify therapeutic insights and accelerate the creation of new medicines.
AI & Machine LearningBiotechSouth San Francisco, US
Daphne Koller(CEO & Founder)Duane Valz(General Counsel)Mary Rozenman(Chief Financial Officer)
BoardVijay Pande(Director)
Board seatRobert Nelsen· per SEC Form D
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.